Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
LY9 belongs to the SLAM family of immunomodulatory receptors (see SLAMF1\; MIM 603492) and interacts with the adaptor molecule SAP (SH2D1A\; MIM 300490) (Graham et al., 2006 [PubMed 16365421]).[supplied by OMIM, Mar 2008].. Additionally we are shipping LY9 Antibodies (159) and LY9 Proteins (16) and many more products for this protein.
Showing 3 out of 10 products:
the results presented here suggest that the tumor suppressor potential of SLAMF3 occurs through activation of Retinoblastoma protein that represses PLK1 (show PLK1 ELISA Kits).
study showed CD229 is overexpressed on the malignant plasma cells of patients across all types of plasma cell dyscrasias including multiple myeloma; CD229 is also expressed on the surface of a fraction of cells carrying the phenotype of chemotherapy-resistant and myeloma-propagating cells within the patients' bone marrow
the Val602 variant of the non-synonymous single nucleotide polymorphism (SNP) rs509749 in the SLAM (show SLAMF1 ELISA Kits) family member CD229 (Ly9, SLAMF3) has a two-fold lower affinity compared with the SLE-associated Met602 variant for the small adaptor protein SAP (show APCS ELISA Kits)
CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance.
Results revealed that SLAMF3 plays a role during hepatitis C virus entry, likely by enhancing entry of viral particle within hepatocytes.
SLAMF3 is an inhibitor of hepatocellular carcinoma cell proliferation and tumor progression.
These results suggest a role for CD319 (show SLAMF7 ELISA Kits) and CD229 in the systemic lupus erythematosus disease process.
Data indicate that the dominance of the SLAMF3/SLAMF6 (show SLAMF6 ELISA Kits) pathway in inducing IL-17A (show IL17A ELISA Kits) production can be attributed to an increased nuclear abundance and recruitment of RORgammat to the IL17A (show IL17A ELISA Kits) promoter.
SLAMF3 and SLAMF6 (show SLAMF6 ELISA Kits) T cell surface expression and IL-17 (show IL17A ELISA Kits) levels significantly correlate with disease activity in systemic lupus erythematosus patients
CD229 is specifically over-expressed on myeloma cells including their clonogenic precursors and contributes to their malignant phenotype.
Ly9/CD229 cell surface receptor emerges as a uniquely important element for modulating innate T cell function, acting as an inhibitory molecule that regulates invariant natural killer (NK)T cell development and innate-like CD8 (show CD8A ELISA Kits) T cell expansion.
Data show that defective tolerance was observed only in Fcgr2b-deficient mice with autoimmune-type Slam (show SLAMF1 ELISA Kits) family genes, indicating that epistatic effects of both genes are involved.
mouse novel Ly9 (show SLAMF7 ELISA Kits) is a new member of the expanding CD150 (show SLAMF1 ELISA Kits) family of cell surface receptors
CD229 is a self-ligand, interacting through its N-terminal V-like domain which contains three amino acid residues critical for the homophilic binding interaction.
CD229 is a pan-lymphocyte marker and indicate that mAbs against CD229 are able to down-modulate T-cell activation.
LY9 belongs to the SLAM family of immunomodulatory receptors (see SLAMF1\; MIM 603492) and interacts with the adaptor molecule SAP (SH2D1A\; MIM 300490) (Graham et al., 2006
lymphocyte antigen 9
, T-lymphocyte surface antigen Ly-9
, T-lymphocyte surface antigen Ly-9-like
, t-lymphocyte surface antigen Ly-9-like
, SLAM family member 3
, cell surface molecule Ly-9
, signaling lymphocytic activation molecule 3